Evidence mapPaperPMID 41599806Full record

ReviewNutrients2026

Therapeutic Advances of Curcumin and Nanocurcumin in Glioblastoma: Molecular Targets, Bioavailability, and Drug Delivery.

Md Ataur Rahman, Mahesh Kumar Yadab, Meser M Ali

Abstract readReview
In one paragraph

Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Md Ataur RahmanDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.ORCID 0000-0001-6649-3694
Mahesh Kumar YadabDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
Meser M AliDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.

Funding

Targeted drug delivery system to overcome blood-brain barrier and therapeutic resistance to current standard of care in GlioblastomaR01CA269607 · WAYNE STATE UNIVERSITY · 2025 to 2025
$512k
NCI NIH HHS R01 CA269607NIH HHS RO1CA269607
6 · The paper itself

Abstract

Glioblastoma (GBM), the most common, invasive, and chemoresistant form of adult primary brain cancer, is characterized by rapid cell proliferation, local invasiveness, and resistance to chemotherapy (e.g., temozolomide (TMZ)) and radiation therapy. Curcumin, a bioactive polyphenol derived from

Indexed as

Antineoplastic AgentsBrain NeoplasmsCurcuminDrug Delivery SystemsGlioblastomaNanoparticlesAnimalsBiological AvailabilityBlood-Brain BarrierHumansNanoparticle Drug Delivery SystemSignal TransductionAntineoplastic AgentsCurcuminnanocurcuminNanoparticle Drug Delivery Systemblood–brain barriercurcumindrug deliveryglioblastomamolecular targetsnanocurcumin

Identifiers

PMID41599806
PMCPMC12844657

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.